Background: Methadone programs have been organized in each Spanish region in a specific way. In spite of the regional interests to manage those programs in a more efficient way, so far the costs of the programs are unknown. As a previous step, it would be desirable to understand the activities related to these programs as well as their respective costs. This article aims to calculate the cost of the Methadone program in the autonomous community of La Rioja, and to understand those parameters which generate a greater cost to this programme.
Methods: The study followed a similar structure as the research recently applied to the region of Murcia. The reference year for the study of the annual costs of the Methadone program was 2010. Data were obtained from different registries of several institutions involved in the regional program. Costs were classified according to different stages and dispensation centres which participated in this programme.
Results: Data analysis, for a concentration of 2 mg/ml of methadone, showed an approximate annual cost of 165.759 euros. Taking the total number of patients into consideration the individual cost was 412,34 euros.
Conclusions: Dispensation is the stage which caused the largest cost to the programme, the highest per patient cost corresponded to the centre with less patients due to the fact that fixed costs are shared by a smaller group of persons; the biggest global cost of the programme came from Logroño's center but its average cost is lower.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4321/S1135-57272012000500008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral lesions and disorders and their prevalence arising from the use of illicit drugs in a prison population.
Acta Odontol Scand
January 2025
Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, Gandra 4585-116, Portugal; UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), Gandra, Portugal.
Background: The dependence on the illicit drugs has been proven to be harmful to the oral cavity and may lead to a series of abnormal manifestations. The main objective of this study was to observe the effects caused by the consumption of illicit drugs in the oral cavity, in a prison population in the North of Portugal.
Methods: A cross-sectional observational study was conducted involving 91 male inmates aged 25-75 years (mean age 41.
"Smoking weed it gets you over the hump": Cannabis co-use as a facilitator of decreased opioid use among people who inject drugs in Los Angeles, California.
Drug Alcohol Depend Rep
September 2024
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Introduction: Opioid overdose mortality rates have surged dramatically in the last decade due largely to fentanyl in the illicit US drug supply. As of June 2024, 38 states, three territories, namely US Virgin Islands, Guam and the Northern Mariana Islands, and the District of Columbia, allow the medical use of cannabis products. However, there remains limited qualitative community-based evidence on the role of cannabis co-use among opioid using and injecting populations.
View Article and Find Full Text PDFBarriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.
PLOS Glob Public Health
January 2025
Yale School of Nursing, Yale University, New Haven, Connecticut, United States of America.
Hepatitis C (HCV) disproportionately affects people who inject drugs (PWID). Despite availability of safe and effective treatment, HCV treatment access and uptake among PWID in low- and middle-income countries (LMICs) has been limited. Understanding the lived experiences of PWID in these settings who have undergone treatment provides the opportunity to gain insight into how to implement treatment programs that meet the needs of this population.
View Article and Find Full Text PDFPatient Challenges in Utilization of Methadone to Treat Opioid Use Disorder and Perspectives on a Solution for Improved Security and Convenience in Take-home Dosing.
Innov Clin Neurosci
December 2024
Mr. Timberlake is with Berkshire Biomedical Corporation in Dallas, Texas.
Background: Methadone is commonly utilized to treat opioid use disorder (OUD). Requirements to visit an opioid treatment provider (OTP) clinic for methadone treatment limits access to treatment, impacts quality of life, and reduces OUD treatment program retention. The Computerized Oral Prescription Administration (COPA) system is a dual-biometric dispensing device for take-home dosing that could reduce the impacts of methadone administration on patients and clinic staff.
View Article and Find Full Text PDFSex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data.
Drug Alcohol Depend
January 2025
Neuropsychoimaging of Addictions and Related Conditions (NARC), Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Question: The opioid epidemic causes massive morbidity, and males have substantially greater overdose mortality rates than females. It is unclear whether there are sex-related disparities at different stages in the trajectory of opioid use disorders (OUD), from large samples in the community.
Goal: To determine sex disparities in non-medical opioid use (NMOU) at the end of treatment with medications for opioid use disorder (MOUD), using national data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!